论文信息 - TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. - 字舞流文

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.

M. Ahn | Y. Ohe | H. Saka | S. Ramalingam | K. Goto | K. Thress | G. Oxnard | H. Mann | L. Horn | M. Frigault | S. Kim | K. Vishwanathan | K. Goto | J.C. Yang | Sang We Kim | D. Ghiorghiu | J. Yang | H. Yu | H. Yu | H. Yu | H. Yu | H. Yu